Biocomposites' STIMULAN® Sets New Standard with EU MDR Certification

KEELE, United Kingdom – February 05, 2026 – Biocomposites has secured a landmark European Union Medical Device Regulation (MDR) certification for its STIMULAN® products, a move that significantly advances the treatment of complex bone and soft tissue infections. The certification validates STIMULAN® Rapid Cure and STIMULAN® Kit for use when mixed with a combination of powerful antibiotics, establishing it as the only calcium matrix in the EU certified to both carry a broad-spectrum antibiotic cocktail and resolve infection.

This regulatory milestone is not just a win for the UK-based company but represents a pivotal moment for surgeons and patients grappling with the devastating effects of musculoskeletal infections.

Conquering Europe's Toughest Regulatory Hurdle

The EU's Medical Device Regulation, known as MDR, represents the most stringent and comprehensive overhaul of medical device oversight in decades. Fully implemented in May 2021, it replaced the previous directive with a framework laser-focused on enhancing patient safety through rigorous requirements for clinical evidence, post-market surveillance, and supply chain traceability. For manufacturers, achieving MDR certification has become a formidable challenge.

The process is particularly demanding for high-risk implantable devices like STIMULAN®. Companies must provide exhaustive clinical data proving safety and performance, often equivalent to that required for new pharmaceuticals. This has been compounded by a significant reduction in the number of Notified Bodies—the independent organizations authorized to assess and certify devices—creating a bottleneck that has delayed or even halted market access for many products.

By successfully navigating this complex and resource-intensive regulatory gauntlet, Biocomposites has demonstrated the robustness of its clinical data and quality management systems. The certification serves as a powerful, third-party validation of STIMULAN®'s safety and efficacy, offering surgeons a level of assurance that is now a prerequisite for operating in the European market.

A New Era of Flexibility in Infection Management

At the heart of this achievement is STIMULAN®'s unique capability. The product is a fully resorbable calcium matrix engineered to release antibiotics directly at the site of infection. Unlike non-resorbable carriers like PMMA bone cement, which often require a second surgery for removal, STIMULAN® dissolves over time, leaving behind new bone growth.

The new MDR certification specifically approves its use when mixed with vancomycin, gentamicin, and tobramycin—either alone or in combination. This is a critical distinction in the field of infection management. Many existing antibiotic carriers are either pre-loaded with a single antibiotic, limiting their scope, or rely on surgeons mixing antibiotics "off-label," without specific regulatory approval for the combination.

STIMULAN®'s certification for combined antibiotic use empowers surgeons with unprecedented flexibility. They can now create a patient-specific, broad-spectrum antibiotic therapy at the point of care, targeting the mix of Gram-positive and Gram-negative bacteria often found in complex or chronic infections like osteomyelitis and periprosthetic joint infections. This allows for a highly targeted assault on pathogens, delivering antibiotic concentrations at the infection site that are thousands of times higher than what can be safely achieved through systemic (intravenous or oral) administration, all while minimizing the risk of systemic side effects.

Reducing the Burden of Secondary Surgeries

The clinical impact of this targeted, high-dose delivery is profound. One of the most significant benefits highlighted by the technology is its potential to resolve infections more effectively in a single procedure, thereby reducing the need for costly and debilitating secondary surgeries.

For patients, avoiding repeat operations means less pain, a lower risk of complications, shorter recovery times, and a faster return to daily life. For surgeons, it means a more reliable tool to achieve infection eradication and improve long-term patient outcomes. The physical and psychological toll of fighting a persistent bone infection, often involving multiple hospital stays and surgeries, is immense. Technologies that can break this cycle represent a fundamental improvement in the standard of care.

With STIMULAN® already used in over 150,000 procedures annually across more than 60 countries, a substantial body of real-world evidence supports its role in infection management strategies. This new, specific EU certification for combined antibiotic use is expected to further solidify its adoption among European clinicians.

Driving Healthcare Efficiency and Market Leadership

Beyond the individual patient, the benefits of STIMULAN®'s approach create a positive ripple effect across the entire healthcare ecosystem. Secondary surgeries and prolonged hospital stays due to unresolved infections are a major driver of healthcare costs. Each additional procedure consumes valuable operating room time, hospital beds, and clinical resources, placing a strain on already burdened health systems.

By improving the efficacy of the initial intervention, STIMULAN® contributes directly to healthcare efficiency. Reducing hospital readmissions and the overall length of treatment translates into significant cost savings for providers and insurers. This economic advantage, coupled with improved patient outcomes, positions the product as a high-value solution in an era of increasing pressure on healthcare budgets.

The MDR certification also provides Biocomposites with a significant competitive edge in the lucrative European medical device market. In a landscape where competitors may offer products for off-label mixing, STIMULAN® stands out as the only calcium matrix with explicit regulatory approval for this advanced, combined-antibiotic application.

As Michael Harris, Chief Executive Officer of Biocomposites, stated in the announcement, "Gaining MDR certification, which reaffirms STIMULAN® as the only calcium matrix antibiotic carrier certified for mixing with a combination of Gram-positive and Gram-negative antibiotics, and also resolve infection in bone and surrounding soft tissue, is tremendous news." He added, "Our world leading calcium sulfate antibiotic carrier is trusted by surgeons across the globe as part of their infection management strategies, helping to improve patient outcomes and decrease hospital readmissions."

This landmark certification not only strengthens Biocomposites' market position but also sets a new benchmark for infection management, promising a future where complex bone infections can be treated more effectively, efficiently, and with a far lower burden on patients.